JPRN-UMIN000026042
Recruiting
N/A
ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitus - Long-term effects of dapagliflozinon glucose metabolism in patients with diabetes mellitus
Kurume University School of Medicine0 sites300 target enrollmentFebruary 8, 2017
Conditionstype 2 diabetes mellitus
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- type 2 diabetes mellitus
- Sponsor
- Kurume University School of Medicine
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Repeated urinary tract infection HbA1c \< 7\.0% BMI \< 22
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Impact of treatment with Dapagliflozin in type 1 diabetic patientsEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
Active, Not Recruiting
Phase 1
Short-term effects of the substance dapagliflozin on the increase of blood sugar concentrations after meal and insulinsensitivity in type 1 diabetic patients.effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasisTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-001441-24-ATMedical University Innsbruck12
Not Yet Recruiting
N/A
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
Completed
Phase 4
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial InfarctionMyocardial InfarctionDiabete Type 2Glucose IntoleranceNCT05050500Qingdao Central Hospital143
Completed
Phase 1
Dapagliflozin Effects on HypoglycemiaType1 Diabetes MellitusNCT03704818University of California, San Diego22